Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from MMF to EC-MPS in Transplant Patients with GI Adverse Events
NCT00149942Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2004
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in kidney transplant rejection and Liver transplant rejection, sponsored by Novartis. Primary endpoint: Gastro-intestinal adverse events at 3 months. Started Oct 2004; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejectionLiver transplant rejection
Beyond the preview
Go deeper on NCT00149942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149942.